Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: Moxonidine and rilmenidine

Journal of Hypertension

Volumn 15, Issue 2, 1997, Pages 117-125

  Van Zwieten, Pieter A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Centrally acting antihypertensives; Clonidine; Imidazoline receptors; Moxonidine; Rilmenidine

Indexed keywords

AGMATINE; ALPHA 2 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; CIRAZOLINE; CLONIDINE; DOPA; EFAROXAN; GUANABENZ; GUANFACINE; IMIDAZOLINE I1 RECEPTOR; KETANSERIN; LOFEXIDINE; MOXONIDINE; OXYMETAZOLINE; RILMENIDINE; URAPIDIL; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTORS; OXAZOLE DERIVATIVE;

ADRENERGIC SYSTEM; ANTIHYPERTENSIVE ACTIVITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DROWSINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERTENSION; LIGAND BINDING; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; ANIMAL; BRAIN;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BRAIN; HUMANS; IMIDAZOLES; OXAZOLES; RECEPTORS, DRUG;

EID: 0030608948     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199715020-00001     Document Type: Review

References (104)

1. Van Zwieten PA, Chalmers JP: Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc Drugs Ther 1994, 8:787-799.
2. Chalmers JP, Pilowski PM: Brain stem and bulbospinal neurotransmitter systems in the control of blood pressure. J Hypertens 1991, 9:675-694.
3. Minson J, Chalmers JP, Drolet G, et al.: Central serotonergic mechanisms in cardiovascular regulation. Cardiovasc Drugs Ther 1989, 4:27-32.
4. Van Zwieten PA, Thoolen MJMC, Timmermans PBMWM: The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 1984, 6 (suppl 11):28-33.
5. Van Zwieten PA, Thoolen MJMC, Timmermans PBMWM: The pharmacological base of the hypotensive activity and side-effects of α-methyl-DOPA, clonidine and guanfacine. Hypertension 1984, 6:11-28.
6. 2-adrenoceptor agonists with a central action. Am J Cardiol 1986, 57:3E-5E.
7. Van Zwieten PA: Different types of centrally acting antihypertensive drugs. Eur Heart J 1992, 13 (suppl A):18-21.
8. Van Zwieten PA: Modulation of sympathetic outflow by centrally acting antihypertensives. Cardiovasc Drugs Ther 1996, 10: 283-289.
9. Julius S, Schork N, Schork A: Sympathetic hyperactivity in early stages of hypertension: the Ann Arbor Data Set. J Cardiovasc Pharmacol 1988, 12 (suppl 3):S121-S129.
10. Julius S, Krause L, Schork N, Mejia AD, Jones KA, van de Ven C, et al.: Myperkinetic borderline hypertension in Tecumseh, Michigan. J Hypertens 1991, 9:77-84.
11. Julius S: Sympathetic overactivity and the pathophysiology of coronary risk in hypertension. Cardiovasc Risk Factors 1995, 5 (suppl 1):2-10.
12. Tibiric(Combining ogonek)a E, Feldman J, Mermet C, Gonon F, Bousquet P: An imidazoline specific mechanism for the hypotensive effect of clonidine: a study with yohimbine and idazoxan. J Pharmacol Exp Ther 1991. 256:606-613.
13. 1A-receptors in the hypotensive response to urapidil. Am J Cardiol 1989, 64:7D-10D.
14. Prichard BNC, Tomlinson B, Renondin JC: Urapidil, a multiple action α-blocking drug. Am J Cardiol 1989, 64:11D-15D.
15. Van Zwieten PA, Mathy MJ, Boddeke HWGM, Doods HN: Central hypotensive activity of ketanserin in cats. J Cardiovasc Pharmacol 1987, 10:S54-S59.
16. Van Zwieten PA, Blauw GJ, van Brummelen P: Serotonergic receptors and drugs in hypertension. Pharmacol Toxicol 1992, 70 (suppl II):S17-S22.
17. Hieble JP, Ruffolo RR: Imidazoline receptors: historical perspective. Fundam Clin Pharmacol 1992, 6 (suppl 1):7S-13S.
18. Feldman J, Tibirica E, Bricca G, Dontenwill M, Belcourt A, Bousquet P: Evidence for the involvement of imidazoline receptors in the central hypotensive effect of rilmenidine in the rabbit Br J Pharmacol 1990, 100:600-604.
19. Bousquet P, Feldman J, Schwartz J: Central cardiovascular effects of α-adrenergic drugs: difference between catecholamines and imidazolines. J Pharmacol Exp Ther 1984, 230:232-236.
20. Michel MC, Ernsberger P: Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol Sci 1992, 13:369-370.
21. Michel MC, Insel PA: Are there multiple imidazoline binding sites? Trends Pharmacol Sci 1989, 10:342-344.
22. Parini A, Moudanos CG, Pizzinat N, Lanier SM: The elusive family of imidazoline binding sites. Trends Pharmacol Sci 1996, 17:13-16.
23. 1-imidazoline sites, J Pharmacol Exp Ther 1993, 264: 172-182.
24. 3H]-RX 821002 (2-methoxy-idazoxan) in the human and rat brains. J Pharmacol Exp Ther 1993, 264:1187-1197.
25. 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 1987, 134:1-13.
26. 2-adrenoceptors and imidazoline binding sites. Brain Res 1990, 514:15-21.
27. Ernsberger P, Meeley MP, Reis DJ: Neuroblastomaglioma hybrid cells contain clonidine displacing substance. Eur J Pharmacol 1989, 174:135-138.
28. Bricca G, Dontenwill M, Molines A, Feldman J, Belcourt A, Bousquet P: The imidazoline preferring receptor: binding studies in bovine, rat and human brain stem. Eur J Pharmacol 1989, 162:1-9.
29. 2 adrenoceptors in the human central nervous system. Neuroscience 1994, 59:589-598.
30. Head GH: Central monoamine systems and new antihypertensive agents. Clin Exp Hypertens 1995, 17:141-152.
31. 2-imidazoline sites. Naunyn Schmiedeberg's Arch Pharmacol 1994, 350:252-257.
32. Mallard HJ, Hudson AL, Nutt DJ: Characterization and autoradiographical localization of non-adrenoceptor binding sites in the rat brain. Br J Pharmacol 1992, 106:1019-1026.
33. 2-imidazoline sites [abstract]. Br J Pharmacol 1994, 111:298P.
34. Olmos G, Miralles A, Barturen F, Garcia-Sevilla JA: The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentrations in rat brain. Br J Pharmacol 1994, 111:997-1002.
35. Regunathan S, Reis DJ: Imidazoline receptors and their endogenous ligands. Ann Rev Pharmacol Toxicol 1996, 36:511-544.
36. Schulz A, Hasselblatt A: An insulin-releasing property of imidazoline derivatives is not limited to compounds that block adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 1989, 340:321-327.
37. 1-imidazoline agonist, moxonidine. Br J Pharmacol 1995, 116:2631-2636.
38. Penner SB, Smyth D: Sodium excretion following central administration of an imidazoline receptor agonist, moxonidine. Br J Pharmacol 1994, 112:1089-1094.
39. Head GA, Sannajust F: Importance of imidazoline receptors in the cardiovascular response to clonidine and rilmenidine in conscious rabbits. Fundam Clin Pharmacol 1992, 6 (suppl D):31S-34S.
40. Atlas D, Burstein Y: Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS Lett 1984, 170:387-390.
41. Atlas D, Burstein Y: Isolation and partial purification of a clonidine displacing brain substance. Eur J Biochem 1984, 144:287-293.
42. Meeley MP, Ernsberger PR, Granata AR, Reis DJ: An endogenous clonidine-displacing substance from bovine brain: receptor binding and hypotensive actions in the ventrolateral medulla. Life Sci 1986, 38:1119-1126.
43. Bousquet P, Feldman J, Atlas D: An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur J Pharmacol 1986, 124.167-170.
44. Bousquet P, Feldman J, Atlas D: Central cardiovascular effects of a non-catecholamine endogenous ligand to clonidine receptors. J Cardiovasc Pharmacol 1987, 10 (suppl 12):S167-S171.
45. Li G, Regunathan S, Barrow CJ, Eshraghi J, Cooper R, Reis DJ: Agmatine: an endogenous clonidine-displacing substance in the brain. Science 1994, 263:966-969.
46. 2-adrenoceptors. Naunyn Schmiedeberg's Arch Pharmacol 1995, 351:10-16.
47. Sun MK, Regunathan S, Reis DJ: Cardiovascular responses to agmatine, a clonidine displacing substance, in anesthetized rat. Clin Exp Hypertens 1995, 17:115-128.
48. Kaan EC, Brückner R, Frohly P, Tulp M, Scharer SG, Ziegler D: Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc Risk Fact 1995, 5 (suppl 1): 19-27.
49. 2-adrenoceptors to imidazoline preferring receptors. Fundam Clin Pharmacol 1992, 6 (suppl 1):1S-63S.
50. 3H]-clonidine to identify imidazoline receptors in the rabbit brain stem. Br J Pharmacol 1993, 110:1537-1543.
51. 1-sites): putative G-protein-linked receptors [abstract]. FASEB J 1991, 5:A1066.
52. Bricca G, Dontenwill M, Molines A, Feldman J, Tibiric(Combining ogonek)a E, Belcourt A, et al.: Rilmenidine selectivity for imidazoline receptors in human brain. Eur J Pharmacol 1989, 163:373-377.
53. 1-imidazoline receptors. J Cardiovasc Pharmacol 1992, 20 (suppl 4):S1-S10.
54. 2-receptors. Eur J Pharmacol 1994, 262:41-48.
55. 1-imidazoline agonist. Cardiovasc Drugs Ther 1994, 8:27-41.
56. Gomez RE, Ernsberger P, Feinland G, Reis DJ: Rilmenidine lowers arterial pressure via imidazole receptors in brain stem C1 area. Eur J Pharmacol 1991, 195:181-191.
57. Van Zwieten PA, Thoolen MJMC, Jonkman FAM, Wilffert B, de Jonge AJ, Timmermans PBMWM: Central and peripheral effects of S 3341 [(N-dicyclopropyl-methylamino-oxazoline)] in animal models. Arch Int Pharmacodyn 1986, 279:130-149.
58. 1-imidazoline receptor agonist. J Cardiovasc Pharmacol 1996, 27 (suppl 3):S26-S37.
59. 1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 1994, 24 (suppl 1)S1-S8.
60. Chan CKS, Head GA: Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. J Hypertens 1996, 14:855-864.
61. Urban R, Szabo B, Starke K: Is the sympathoinhibitory effect of rilmenidine mediated by alpha-2 adrenoceptors or imidazoline receptors? J Pharmacol Exp Ther 1994, 270:572-578.
62. 2-adrenoceptors in the cardiovascular effects of moxonidine. Eur J Pharmacol 1995, 282:19-28.
63. 1-receptors in the ventrolateral medulla and their role in cardiorespiratory control. Adv Lung Biol 1995, 82:319-358.
64. 2-auto-receptors are involved in the blood pressure lowering effect of moxonidine. J Cardiovasc Pharmacol 1990, 16:15-22.
65. Chrisp P, Failds D: Moxonidine. Drugs 1992, 44:993-1012.
66. 2-receptor selectivity and specificity of the antihypertensive agent moxonidine. Arzneimittel Forsch 1988, 38:1435-1442.
67. Armah IB, Hofferbert E, Stenzel W: General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittel Forsch 1988, 38:1426-1434.
68. Head GA, Burke SB: Importance of noradrenergic and serotonergic pathways in the cardiovascular actions of rilmenidine and clonidine. J Cardiovasc Pharmacol 1991, 18:819-826.
69. Bousquet P, Reid JL: Imidazoline receptors in a comprehensive approach to hypertension. J Cardiovasc Pharmacol 1995, 26 (suppl 2):S1-S67.
70. Rupp H, Turcani M, Jacob R: Caloric intake and radio telemetrically assessed high blood pressure. Pharm Pharmacol Lett 1993, 3:103-106
71. Rupp H, Dhalla KS, Dhalla NS: Mechanisms of cardiac cell damage due to catecholamines: significance of drugs regulating central sympathetic outflow. J Cardiovasc Pharmacol 1994, 24 (suppl 1):S16-S24.
72. Lepran I, Papp JG: Effect of moxonidine on arrhythmias induced by coronary artery occlusion and reperfusion. J Cardiovasc Pharmacol 1994, 24 (suppl 1):S9-S15.
73. Mammoto T, Kamibayashi T, Hayashi Y, Takada K, Yamatodani A, Yoshiya I: Rilmenidine prevents epinephrine-induced arrhythmias in halothane-anesthetized dogs. J Cardiovasc Pharmacol 1995, 26 (suppl 2):S40-S43.
74. Wenzel RR, Qui S, Spieker L, Lüscher TF, Noll G: Moxonidine decreases both cardiac and peripheral sympathetic activity in healthy volunteers [abstract]. Kidney Blood Press Res 1996, 19:63.
75. 1-imidazoline receptor agonist, moxonidine. Br J Pharmacol 1994, 112:1089-1094.
76. 1-imidazoline-binding sites in rabbit proximal tubule cells. J Cardiovasc Pharmacol 1995, 26 (suppl 2):S59-S62.
77. 1-imidazoline receptor-selective compounds mediate natriuresis in the rat J Cardiovasc Pharmacol 1995, 26 (suppl 2):S63-S67.
78. Thoolen MJMC, Timmermans PBMWM, van Zwieten PA: Discontinuation syndrome after continuous infusion of clonidine in the spontaneously hypertensive rat. Life Sci 1981, 28:2103-2109.
79. Thoolen MJMC, Timmermans PBMWM, van Zwieten PA: Guanfacine and clonidine: antihypertensive and withdrawal characteristics after continuous infusion and its interruption in the spontaneously hypertensive and normotensive rat. Naunyn Schmiedeberg's Arch Pharmacol 1982, 319:82-86.
80. Thoolen MJMC, Hendriks JCA, Timmermans PBMWM, van Zwieten PA: Precipitation by yohimbine of the withdrawal syndromes of clonidine, guanfacine and methyldopa in the spontaneously hypertensive rat. J Cardiovasc Pharmacol 1983, 5:224-228.
81. Webster J, Kovk HF: Rebound and aspects of tolerability of centrally acting antihypertensive drugs. J Cardiovasc Pharmacol 1996, 27 (suppl 3):S49-S54.
82. Jarrott B, Lewis SJ, Doyle AE, Louis WJ: Effects of continuous infusions (10 days) and cessation of infusions of clonidine and rilmenidine on cardiovascular and behavioral parameters of spontaneously hypertensive rats. Am J Cardiol 1988, 61:39D-44D.
83. Ernsberger P, Koletsky RJ, Collins LA, Bedol D: Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent Cardiovasc Drugs Ther 1997, in press.
84. Schäfer SG, Christen MO, Ernsberger P: The second generation of centrally acting drugs. J Cardiovasc Pharmacol 1992, 20 (suppl 4):vii-viii.
85. Koenig-Berard E, Tierney C, Beau C, Delbarre G, Lhoste F, Labrid C: Cardiovascular and central nervous system effects of rilmenidine in rats. Am J Cardiol 1988, 61:22D-23D.
86. Theodor RA, Weimann HJ, Weber W, Michaelis K: Absolute bioavailability of moxonidine. Eur J Drug Metab Pharmacokin 1991, 16:153-159.
87. Theodor RA, Weimann HJ, Weber W, Müller M, Michaelis K: Influence of food on the oral bioavailability of moxonidine. Eur J Drug Metab Pharmacokin 1992, 17:61-61.
88. Trenk D, Wagner J, Jähnchen E, Plänitz V: Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers. J Clin Pharmacol 1987, 27:988-993.
89. Kirch W, Hutt HJ, Plänitz V: Pharmacodynamic action and pharmacodynamics after single oral administration in hypertensive patients. J Clin Pharmacol 1990, 30:1088-1095.
90. Weimann HJ, Rudolph M: Clinical pharmacokinetics of moxonidine. J Cardiovasc Pharmacol 1992, 20 (suppl 4):S37-S41.
91. Dollery CT, Davies DS, Duchier J, Pannier B, Safar M: Dose and concentration-effect relations for rilmenidine. Am J Cardiol 1988, 61:60D-66D.
92. Lins RL, Daelemans R, Dratwa M, Verbeelen D, Sennesael J: Acceptability of rilmenidine and long term surveillance of plasrna concentrations in hypertensive patients with renal insufficiency. Am J Med 1987, 87 (suppl 3C):41S-45S.
93. Genissel P, Bromet N, Fourtillan JB, Mignot A, Albin H: Pharmacokinetics of rilmenidine in healthy subjects. Am J Cardiol 1988, 61:47D-53D.
94. Prichard BNC, Graham BR: Effective antihypertensive therapy: blood pressure control with moxonidine. J Cardiovasc Pharmacol 1996, 27 (suppl 3):S38-S48.
95. Mitrovic V, Patyna W, Muting J, Schlepper M: Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension. Cardiovasc Drugs Ther 1991, 5:967-972.
96. Eichstädt H, Richter W, Bäder W: Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc Drugs Ther 1989, 3:583-587.
97. Olivier JP, Christen MO, Schäfer SG: Moxonidine: a second generation of centrally acting drugs. An appraisal of clinical experience. J Cardiovasc Pharmacol 1992, 20 (suppl 4):S31-S36.
98. Kirch H, Hutt HJ, Plänitz V: Pharmacodynamic action and pharmacokinetics of moxonidine after single oral administration in hypertensive patients. J Clin Pharmacol 1990, 30:1088-1095.
99. N'Guyen Van Cao A, Levy B, Slama R: Non-invasive study of cardiac structure and function after rilmenidine for essential hypertension. Am J Cardiol 1988, 61:72D-75D.
100. Head GA: Baroreflexes and cardiovascular regulation in hypertension. J Cardiovasc Pharmacol 1995, 26 (suppl 2):S7-S16.
101. Trimarco B, Morisco C, Sarno D, lovino G, Argenziano L, Russo R, et al.: Rilmenidine in patients with left ventricular hypertrophy: beyond the reduction of left ventricular mass. J Cardiovasc Pharmacol 1995, 26 (suppl 2):S29-S33.
102. Scemama M, Février B, Beucler I, Dairou F: Lipid profile and antihypertensive efficacy in hyperlipidemic hypertensive patients: comparison of rilmenidine and captopril. J Cardiovasc Pharmacol 1995, 26 (suppl 2):S34-S39.
103. Harron DWG, Hasson B, Regan M, McClelland RJ, King DJ: Effects of rilmenidine and clonidine on the electroencephalogram, saccadic eye movements, and psychomotor function. J Cardiovasc Pharmacol 1995, 26 (suppl 2):S48-S54.
104. Fillastre JP, Vanhoutte PM: Second International Symposium on Rilmenidine. Am J Med 1989, 87 (3C):1S-74S.